Approval · Notice of Compliance 16046 · 2014
YERVOY: Notice of Compliance 16046
Issued September 10, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16046
- Date
- September 10, 2014
- Company
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revised indication:: yervoy (ipilimubab) is indicated for the treatment of unresectable or metastatic melanoma
- Therapeutic class
- Antineoplastic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| YERVOY | Not yet assigned | — |
Medicinal ingredients
- IPILIMUMAB 5 MG per ML